Traws Pharma, Inc. (NASDAQ: TRAW)

Sector: Healthcare Industry: Biotechnology CIK: 0001130598
Market Cap 1.88 Mn
P/B 0.41
P/E 0.02
P/S 0.66
ROIC (Qtr) -246.51
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 0.00
Debt/Equity (Qtr) 0.00
Add ratio to table...

About

Investment thesis

Bull case

  • Robust tangible asset base of 9.87M provides 5.68x coverage of working capital 1.74M, indicating strong operational backing.
  • Cash reserves of 6.42M provide solid 583.64x coverage of other non-current liabilities 11000, indicating strong liquidity.
  • Strong cash position of 6.42M provides 2.31x coverage of other current liabilities 2.78M, indicating excellent liquidity.
  • Cash reserves of 6.42M provide robust 0.81x coverage of current liabilities 7.89M, indicating strong short-term solvency.
  • Cash position of 6.42M represents healthy 3.69x of working capital 1.74M, demonstrating strong operational liquidity.

Bear case

  • Investment activities of (2.58M) provide weak support for R&D spending of 8.97M, which is -0.29x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (19.47M) shows concerning coverage of stock compensation expenses of 735000, with a -26.49 ratio indicating potential earnings quality issues.
  • Retained earnings of (632.54M) provide limited buffer against comprehensive income items of 6000, which is -105423.50x, indicating elevated exposure to market risks.
  • Operating cash flow of (19.47M) shows concerning coverage of minority interest expenses of (106.66M), which is 0.18x, suggesting complex corporate structure risks.
  • High financing cash flow of 23.02M relative to working capital of 1.74M, which is 13.25x suggests concerning dependence on external funding for operational needs.

Type of Arrangement and Non-arrangement Transactions Breakdown of Revenue (2024)

Segments Breakdown of Revenue (2024)

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets -0.90 11.06
EV to Cash from Ops. EV/CFO 0.58 26.32
EV to Debt EV to Debt 0.00 762.61
EV to EBIT EV/EBIT -0.12 -13.49
EV to EBITDA EV/EBITDA 0.71 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF 0.58 25.66
EV to Market Cap EV to Market Cap -5.96 203.37
EV to Revenue EV/Rev -3.94 156.31
Price to Book Value [P/B] P/B 0.41 20.59
Price to Earnings [P/E] P/E 0.02 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) 0.00 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 18.67 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 397.54 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 88.86 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) 397.54 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) 397.54 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) 395.90 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) 35.50 -40.48
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 1,159.29 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.23 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 0.81 3.92
Current Ratio Curr Ratio (Qtr) 1.22 7.33
Debt to Equity Ratio Debt/Equity (Qtr) 0.00 0.48
Interest Cover Ratio Int Coverage (Qtr) 0.00 956.66
Times Interest Earned Times Interest Earned (Qtr) 0.00 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 3,280.70 -17,888.70
EBIT Margin % EBIT Margin % (Qtr) 3,280.04 -18,246.34
EBT Margin % EBT Margin % (Qtr) 3,280.04 -19,108.08
Gross Margin % Gross Margin % (Qtr) 100.00 -10.30
Net Profit Margin % Net Margin % (Qtr) 3,280.00 -19,056.96